PARIS, Nov. 30, 2010 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, will today host an R&D day for investors, analysts and the media at its headquarters, near Paris.
Following a tour of its proprietary meganuclease technical platform, members of Cellectis’ management and scientific teams will detail the activities within its core business areas including: meganuclease engineering technology, research tools, genome engineering in plants and therapeutic programs. Guest speaker, Dr. Serge Braun from the French Muscular Dystrophy Association (AFM), will provide an update on its collaboration with Cellectis in therapeutics. Finally, the potential applications of induced pluripotent stem cell (iPS) technologies, recently licensed from Academia Japan, will also be described.
Registration will commence at 11.00AM CET and presentations will be available shortly after the event at www.cellectis.com/investors/accounts-and-reports.
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.
More information at www.cellectis.com.
Follow Cellectis on Twitter at www.twitter.com/cellectis.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers (“AMF”) granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis
